Want to see HUM full AI Analyst Report?
HUM Stock Chart & Stats
$389.32
-$6.72(-1.73%)
At close: 4:00 PM EDT
$389.32
-$6.72(-1.73%)
Day’s Range― - ―
52-Week Range$163.11 - $428.88
Previous CloseN/A
Volume391.94K
Average Volume (3M)1.36M
Market Cap
$45.50B
Enterprise Value$62.43K
Total Cash (Recent Filing)$23.87B
Total Debt (Recent Filing)$14.25B
Price to Earnings (P/E)35.6
Beta0.84
Next Earnings
Nov 06, 2026EPS Estimate
-0.95Next Dividend Ex-DateN/A
Dividend Yield0.93%
Share Statistics
EPS (TTM)10.65
Shares Outstanding120,080,310
10 Day Avg. Volume1,241,617
30 Day Avg. Volume1,362,862
Financial Highlights & Ratios
PEG Ratio-18.55
Price to Book (P/B)1.75
Price to Sales (P/S)0.24
P/FCF Ratio82.27
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$429.86Price Target Upside10.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering23
EPS Forecast (FY)9.15
Revenue Forecast (FY)$162.49B
Bulls Say, Bears Say
Bulls Say
Government-backed GrowthHumana continues expanding in Medicare Advantage and other government-backed programs, supporting durable revenue visibility. Membership growth and recurring CMS-related payments can strengthen scale, customer reach, and long-term care-management economics.
Cost Discipline And Margin RecoveryOperating-model changes, centralized utilization management, outsourcing, and vendor simplification are producing measurable savings. Sustained execution could rebuild profitability from depressed levels and support management’s 2028 margin-recovery objective.
Healthcare Platform ExpansionExpanding Medicaid coverage and CenterWell’s primary-care base deepen Humana’s presence across insurance and care delivery. Greater scale can improve member engagement, support value-based arrangements, and enhance control of medical costs over time.
Bears Say
Severe Profitability CompressionThe business remains profitable, but sharply lower margins and returns indicate reduced earnings power. Thin profitability leaves less protection against medical-cost volatility, policy changes, or unfavorable membership mix and makes recovery dependent on sustained execution.
Elevated Prescription-cost InflationPersistent drug-cost inflation can widen the gap between premiums and claims, pressuring underwriting margins in Medicare and Part D. Higher costs may require benefit reductions, pricing actions, or tighter utilization management that could affect competitiveness.
Membership And Reserving UncertaintyLarge plan exits create retention and mix risk, while elevated IBNR signals uncertainty around ultimate medical claims. Even with historical recapture, disruption and reserve development could delay margin recovery and reduce visibility into future earnings.
HUM FAQ
What was Humana Inc’s price range in the past 12 months?
Humana Inc lowest stock price was $163.11 and its highest was $428.88 in the past 12 months.
What is Humana Inc’s market cap?
Humana Inc’s market cap is $45.50B.
When is Humana Inc’s upcoming earnings report date?
Humana Inc’s upcoming earnings report date is Nov 06, 2026 which is in 75 days.
How were Humana Inc’s earnings last quarter?
Humana Inc released its earnings results on Jul 29, 2026. The company reported $7.61 earnings per share for the quarter, beating the consensus estimate of $7.268 by $0.342.
Is Humana Inc overvalued?
According to Wall Street analysts Humana Inc’s price is currently Undervalued.
Does Humana Inc pay dividends?
Humana Inc pays a Quarterly dividend of $0.885 which represents an annual dividend yield of 0.93%. See more information on Humana Inc dividends here
What is Humana Inc’s EPS estimate?
Humana Inc’s EPS estimate is -0.95.
How many shares outstanding does Humana Inc have?
Humana Inc has 120,080,310 shares outstanding.
What happened to Humana Inc’s price movement after its last earnings report?
Humana Inc reported an EPS of $7.61 in its last earnings report, beating expectations of $7.268. Following the earnings report the stock price went down -5.994%.
Which hedge fund is a major shareholder of Humana Inc?
Currently, no hedge funds are holding shares in HUM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Humana Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$429.86 (10.41% Upside)
$429.86 (10.41% Upside)
Blogger Sentiment
Bullish
HUM Sentiment 82%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Decreased
By 583.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.47%
12-Months-Change
Fundamentals
Return on Equity
0.93%
Trailing 12-Months
Asset Growth
13.58%
Trailing 12-Months
Company Description
Humana Inc
Humana Inc., a prominent health and well-being enterprise, operates across the United States through its various subsidiary companies. Its operational structure is divided into three main segments: Retail, Group and Specialty, and Healthcare Services. The firm provides a wide array of medical and supplementary insurance plans directly to individual consumers. Furthermore, Humana collaborates with government entities; it holds a contract with the Centers for Medicare and Medicaid Services (CMS) to manage the Limited Income Newly Eligible Transition (LI NET) prescription drug program. The company also secures agreements with numerous states to deliver Medicaid, dual-eligible, and long-term care support benefits. For employer groups and individuals, Humana furnishes fully insured commercial medical and specialized health coverage, which encompasses dental, vision, and other ancillary health benefits. They additionally offer administrative services only (ASO) solutions and extend support to military personnel through contracts like the TRICARE T2017 East Region. Beyond insurance products, the company delivers comprehensive healthcare services directly. These include pharmacy management, provider network services, and a suite of home-based solutions such as home health care, serving both its own health plan enrollees and external clients. By the close of 2021 (December 31), Humana's reach extended to approximately 17 million individuals enrolled in its medical benefit plans and an additional 5 million utilizing its specialized product offerings. Established in 1961, Humana Inc. maintains its corporate headquarters in Louisville, Kentucky.
HUM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally constructive operational and strategic progress narrative: clear cost-reduction execution (120 bps Y/Y improvement in Q2 operating cost ratio and expected ~150 bps full-year), tangible improvement in key Stars-related measures (outperforming historical CAGR on most selected metrics and ~5% better quality improvement rate for BY '29 measures), balance-sheet moves (Gentiva divestiture ~ $900M and $1.5B P-Cap facilities) and a new statewide Medicaid win. However, material risks remain — notably elevated and rising drug trend, dependence on membership mix for margin realization, plan-exit disruption (~600k members), elevated reserves/IBNR, and Stars/ policy uncertainty — which temper the outlook. On balance, the highlights (execution, cost savings, Stars operational progress, capital actions) outweigh the lowlights (policy uncertainty, drug trend, membership disruption), producing a cautiously positive sentiment.View all HUM earnings summariesHUM Revenue Breakdown
94.73% Premiums
4.50% Services
0.78% Investment income

HUM Stock 12 Month Forecast
Average Price Target
$429.86
▲(10.41% Upside)
Technical Analysis
Ownership Overview
0.26% Insiders
35.99% Mutual Funds
35.94% Other Institutional Investors
0.02% Public Companies and
Individual Investors










